0102030405
Velpatasvir CAS No. 1377049-84-7 Pharmaceutical API
02
introduce
Velpatasvir is a potent pan-genotypic HCV NS5A inhibitor and core antiviral pharmaceutical API. As a direct-acting antiviral (DAA), it is commonly used in combination with Sofosbuvir to treat chronic hepatitis C of all six major genotypes.
Our products comply with strict international pharmaceutical standards to ensure high purity, stable efficacy and reliable supply for clinical treatment and pharmaceutical formulation.
02
Physical and chemical properties
Velpatasvir possesses key physical and chemical characteristics as follows:
- Melting Point: >170 °C (decomposes)
- Density: 1.314±0.06 g/cm³ (Predicted)
- Storage Condition: Store at -20°C, sealed and protected from light
- Solubility: Soluble in DMSO (>25 mg/mL)
- Stability: Stable for 1 year under recommended storage conditions; DMSO solutions can be stored at -20°C for up to 3 months
- Melting Point: >170 °C (decomposes)
- Density: 1.314±0.06 g/cm³ (Predicted)
- Storage Condition: Store at -20°C, sealed and protected from light
- Solubility: Soluble in DMSO (>25 mg/mL)
- Stability: Stable for 1 year under recommended storage conditions; DMSO solutions can be stored at -20°C for up to 3 months
Pan-Genotypic Activity
Effectively inhibits all six major genotypes of hepatitis C virus (HCV), eliminating the need for genotype testing before treatment.
Effectively inhibits all six major genotypes of hepatitis C virus (HCV), eliminating the need for genotype testing before treatment.
High Antiviral Potency
It has extremely strong antiviral effect, exhibits strong inhibitory activity against HCV for genotypes 1-4, 6a. When used alone or in combination with other drugs, the cure rate of hepatitis C can reach 97%-98%.
High Drug Resistance Barrier
It has excellent anti-drug resistance ability and is not easy to have viral drug-resistant mutations. It is more stable and reliable for long-term treatment.
Flexible Application
As a second-generation NS5A inhibitor, it has good antiviral activity against common NS5A mutations and drug-resistant mutations.
It is mainly used for the treatment of hepatitis C virus (HCV) infection. The treatment mechanism is: as an NS5A inhibitor, it inhibits the NS5A protein of hepatitis C virus, blocks viral replication, and thus achieves the effect of eliminating the virus and curing hepatitis C. The specific applications include:
Hepatitis C Treatment: Used for the treatment of adult patients infected with genotype 1-6 hepatitis C virus, suitable for hepatitis C populations with different genotypes; for patients without cirrhosis or with compensated cirrhosis, it can be used alone; for patients with decompensated cirrhosis, it can be used in combination with ribavirin to improve the therapeutic effect.
Potential Application: In vitro studies have shown that it can bind to the spike protein of COVID-19 (SARS-CoV-2), and may become a potential drug for the treatment of COVID-19 in the future. Relevant research is still under exploration.
Adjunctive Application: When used in combination with sofosbuvir, it can inhibit liver fibrosis in non-hepatitis C-related animal models and assist in protecting liver function.
Hepatitis C Treatment: Used for the treatment of adult patients infected with genotype 1-6 hepatitis C virus, suitable for hepatitis C populations with different genotypes; for patients without cirrhosis or with compensated cirrhosis, it can be used alone; for patients with decompensated cirrhosis, it can be used in combination with ribavirin to improve the therapeutic effect.
Potential Application: In vitro studies have shown that it can bind to the spike protein of COVID-19 (SARS-CoV-2), and may become a potential drug for the treatment of COVID-19 in the future. Relevant research is still under exploration.
Adjunctive Application: When used in combination with sofosbuvir, it can inhibit liver fibrosis in non-hepatitis C-related animal models and assist in protecting liver function.
We implement strict full-process quality inspection, with each batch of Velpatasvir undergoing rigorous testing on key indicators such as purity solubility and impurity content to meet international pharmaceutical standards. Equipped with a stable raw material supply chain and advanced pharmaceutical-grade production facilities, we ensure continuous large-scale supply.
Our professional technical team provides tailored services including formulation optimization, application guidance and post-sales technical support for pharmaceutical enterprises, clinical institutions and research laboratories.
Our professional technical team provides tailored services including formulation optimization, application guidance and post-sales technical support for pharmaceutical enterprises, clinical institutions and research laboratories.
As a pioneering pan-genotypic HCV NS5A inhibitor, Velpatasvir has revolutionized the treatment of chronic hepatitis C with its broad genotype coverage, high efficacy and excellent resistance barrier. It plays an irreplaceable core role in antiviral therapy, enabling effective treatment of all HCV genotypes without prior genotype testing.
With stable product quality, reliable supply capacity and professional technical services, we are committed to providing high-quality Velpatasvir API for global customers. Choose our Velpatasvir to meet your needs in pharmaceutical formulation, clinical treatment and biomedical research. Contact us for more product details and cooperation support.
With stable product quality, reliable supply capacity and professional technical services, we are committed to providing high-quality Velpatasvir API for global customers. Choose our Velpatasvir to meet your needs in pharmaceutical formulation, clinical treatment and biomedical research. Contact us for more product details and cooperation support.